Education only. Not investment or medical advice.
What you'll learn today:
What OpenAI's AI agents found in 32 minutes, and which public companies work with the AI labs
How an AI read 10 million health records to find aging targets, and the drugmaker that licensed them
Plus: an investor tip, quick hits and dated milestones
Read time: 5 minutes
Longevity Biotechs On The Move
AI AND AGING
OpenAI's AI Agents Did Months Of Brain Research In 32 Minutes
Source: OpenAI, Oct 21, 2026; Fierce Biotech, Apr 2026; MIT Technology Review, Jun 30, 2026
EverLife: Could it add healthy years? Today OpenAI said thousands of AI agents running its biology model, GPT-Rosalind, combed a CRISPR atlas of millions of mouse brain cells in 32 minutes. The authors estimate the same work would take people months to a year. The agents flagged leads tied to Perry syndrome, a Parkinson's-like disease, and to mTOR, a well-known aging pathway. Is the business strong? The money is in who uses these tools: Amgen, Moderna and Thermo Fisher already work with GPT-Rosalind, and Novo Nordisk signed on in April.
Key Points:
These are research leads, not proven results. Each still needs lab testing.
Anthropic launched Claude Science on June 30 and plans its own early drug programs for rare diseases.
Alphabet's Isomorphic Labs targets its first human trials by the end of 2026, a year later than first said.
Details: A reality check: in a test of aging biology published in Cell on Sept 17, all 18 frontier AI models tested, from OpenAI, Google, Anthropic and xAI, failed to predict biological age from raw lab data. Small specialized models did better, though the group that built the test also built those models.
Where it trades: OpenAI and Anthropic are private. Public ways in include Alphabet (NASDAQ: GOOGL), Amgen (NASDAQ: AMGN), Moderna (NASDAQ: MRNA) and Thermo Fisher (NYSE: TMO). In each, AI drug work is a small part of the business.
What it means for your health: Faster discovery means more aging-related drug ideas reach testing sooner. AI does not shorten human trials.
What it means for your money: The leaders are private, so public exposure is indirect. Today's Investor Tip covers how to judge that.
Reader pick: Want to keep up with the AI tools now speeding up aging research, without reading tech news all day? The Deep View sums up what matters in AI every morning and is read by 600,000+ professionals. Subscribe free with one click →
CELL REJUVENATION
A $3.1B Startup Plans To Rejuvenate Aging Livers In People Next Year
Source: NewLimit via X, Jun 2, 2026; Quartz, Jun 3; Longevity.Technology, Jun 3
EverLife: Could it add healthy years? NewLimit is developing therapies that reset the age markers inside cells, starting with the liver. It says preclinical work reversed signs of cellular age in older human liver cells, and its first human study is expected to focus on fatty liver disease. Is the business strong? Investors put in $435M in June at a $3.1B valuation, more than triple its value a year earlier.
Key Points:
Round led by Founders Fund, with Thrive Capital, Kleiner Perkins and Eli Lilly's venture arm
Co-founded by Coinbase CEO Brian Armstrong
First human trial planned for 2027
Details: There is no human data yet. The liver is a practical first target: fatty liver disease is widespread, and liver health can be tracked with blood tests and scans.
Where it trades: Private, so most readers can't invest yet. Eli Lilly (NYSE: LLY) invested through Lilly Ventures.
What it means for your health: If resetting cell age works in the liver, it opens the door to testing in other organs that wear out with age.
What it means for your money: A $3.1B valuation before any human data means investors are paying for success not yet shown in people. The 2027 trial is the first real test.
Reader pick: Startups like NewLimit raise money privately for years before any public listing. Alternative Investing Report covers that private side of the market every morning and is read by 95,000+ investors. Subscribe free with one click →
AI AGING TARGETS
An AI Read 10 Million Health Records To Find Aging Targets. Roche's Chugai Licensed Them.
Source: Gero via Business Wire, Jun 17, 2026; Pharmaceutical Technology, Jul 8, 2025
EverLife: Could it add healthy years? Singapore-based Gero trains AI on about 10 million long-term medical records to find "hub" drivers shared by several age-related diseases, so one drug might slow more than one illness. Is the business strong? Chugai, a Roche Group company, licensed antibodies against Gero's targets for an upfront payment, up to $250M in milestones, and royalties.
Key Points:
Gero raised $17M in June, bringing total equity funding to $34M
It ran an earlier research collaboration with Pfizer in 2023
All programs are preclinical, with no human testing yet
Details: Milestone totals are the most a deal could pay if every goal is met, and the upfront amount was not disclosed. Judge licensing deals by the upfront cash first.
Where it trades: Gero is private. Chugai trades in Tokyo (TSE: 4519). Roche, its majority owner, trades in Switzerland (SIX: ROG) and over the counter in the US (RHHBY).
What it means for your health: Targets that drive several age-related diseases at once are the closest thing yet to treating aging itself.
What it means for your money: For Gero, income depends on Chugai hitting milestones. For Chugai and Roche, this is one small early program among many.
Sponsored: Drugs aimed at aging targets are still years away, but GLP-1 medicines are already widely used today. If you’ve wondered whether one is right for you, MEDVi matches you with a licensed clinician who reviews your health history and builds a plan, starting at $99 (US only). See if you qualify →
You Pick The Next Story
Which AI-and-aging story should I dig into next?
Investor Tip
When the leaders are private, look at who sells them the tools.
In the early internet, many investors who couldn't buy the hottest startups owned their suppliers instead. The same pattern exists here: lab-equipment makers, data providers and big-drug-company partners. Before you count one as exposure, check two things: what share of its revenue actually comes from this trend, and whether the partnership has paid real money or is only a press release.
Longevity 101: What AI Speeds Up In Drug Development, And What It Can't
What it speeds up: finding a target, designing molecules and choosing which candidates are worth making. This used to take years of trial and error.
What it can't skip: human trials. Safety and benefit still have to be shown in people. Developing a drug typically takes 10 to 15 years in total, according to the industry group PhRMA, and most of that time is spent in trials.
How to use it: When a company says "AI-discovered," ask how far the drug has gotten in people. An AI-designed drug in early trials carries the same risk as any other early-stage drug.
Quick Hits
Anthropic (private): bought AI biotech startup Coefficient Bio, reportedly for about $400M.
OpenAI (private): opened a GPT-Rosalind plan for academic labs on Oct 15, with sponsored access for eligible US university labs.
On The Calendar
End of 2026: Isomorphic Labs' first human trials (company target)
2027: NewLimit's first human trial, in the liver
For Members
Members get my 25-point health and business scores on longevity companies and see which ones I'm watching most closely.
How was today's issue?
Know someone who wants more healthy years? Forward this. Got this from a friend? Join free here.
Hit reply and tell me: would you trust an AI-discovered drug more, less or the same as a traditional one? I read every reply.
Eric
This newsletter is general and impersonal. Nothing in it is a recommendation to buy, sell or hold any security, and it doesn't consider your circumstances. Nothing here is an offer to sell or a solicitation of an offer to buy any security. Company plans and dates are the companies' own statements, not my forecasts.
I hold no position in, and receive no pay from, any company named here. I hold personal equity in Repair Biotechnologies and Yuva Biosciences, neither discussed here. This issue was drafted with AI assistance, including Claude by Anthropic, a company named above. Treatments mentioned are experimental unless noted as approved.
EverLife may earn a fee from links in this issue, and we only recommend things we believe benefit readers.